Updated Review,US regulators have approved an oral version of Wegovy

October 2025 has proven to be a pivotal month for semaglutide, a groundbreaking medication that continues to reshape the landscape of obesity and type 2 diabetes treatment. This period has seen a flurry of new developments, including significant regulatory approvals, promising clinical trial data, and evolving market dynamics, underscoring the drug's growing impact. Novo Nordisk, the pharmaceutical giant behind semaglutide, has been at the forefront of these advancements, consistently pushing the boundaries of what's possible in metabolic health.

One of the most significant pieces of semaglutide news today from October 2025 is the US Food and Drug Administration's (FDA) approval of semaglutide 7 mg and 14 mg for cardiovascular risk reduction in patients with type 2 diabetes, irrespective of their prior diabetes status. This landmark decision, reported on Oct. 17, 2025, marks a crucial expansion of semaglutide's therapeutic applications beyond glycemic control and weight management, highlighting its multifaceted cardiometabolic benefits. The approval was supported by data from trials demonstrating a significant reduction in the risk of major adverse cardiovascular events.

Further solidifying semaglutide's presence, Novo Nordisk Presents Four New Analyses on Oral Semaglutide 25 mg at ObesityWeek® 2025. These analyses, focusing on the oral formulation of semaglutide, often referred to as Wegovy® in a Pill, provide deeper insights into its efficacy and safety profile for managing obesity. The OASIS 4 trial specifically is shedding light on the cardiometabolic health benefits among adults with obesity or overweight, indicating a broader impact than previously understood. The continuous development of oral semaglutide is a key focus, with US regulators have approved an oral version of Wegovy for chronic weight management, positioning it as the first daily pill in its drug class. This development is anticipated to significantly enhance patient adherence and convenience.

The news around semaglutide extends to its efficacy in weight loss. Trials like STEP UP have revealed that a higher dose of semaglutide, specifically 7.2 mg, led to greater weight loss compared to the current approved 2.4 mg dose. This suggests a dose-dependent response and opens avenues for optimizing treatment regimens. Furthermore, Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in new indirect comparisons, reinforcing its competitive edge.

Beyond approvals and efficacy data, October 2025 has also seen discussions regarding the broader market and accessibility of semaglutide. Reports indicate a potential "massive shake-up is underway in India's obesity and diabetes drug market as the patent for Semaglutide is nearing its expiry. This could pave the way for increased competition and potentially more affordable access to the drug in the region. While global sales revenue for Ozempic and Wegovy were substantial in 2025, the expiration of patents could lead to significant shifts.

However, the journey with semaglutide is not without its challenges. Real-world studies continue to highlight that a considerable percentage of patients discontinue the medication within a year, with cost and side effects being top reasons for quitting GLP-1s for obesity. This underscores the importance of ongoing research into mitigating side effects and improving patient support. Despite these hurdles, the potential of GLP-1 drugs like semaglutide and tirzepatide as first-line options when substantial weight loss is needed is recognized, potentially shifting prescribing patterns and payer coverage.

Looking ahead, the pipeline for new weight-loss drugs is robust. While some promising candidates like CagriSema are still in development, with disappointing data from trials in December affecting early optimism, hopes remain high for future innovations. New GLP-1 weight-loss drugs are coming—and they're expected to target multiple gut hormones, potentially offering even greater weight loss than current treatments.

In summary, semaglutide news today in October 2025 paints a picture of a drug class that is not only maturing but also expanding its reach and impact. From critical regulatory approvals for cardiovascular risk reduction and the introduction of oral formulations to ongoing research into optimizing dosages and addressing real-world challenges, semaglutide continues to be a central focus in the fight against obesity and type 2 diabetes. The ongoing advancements, including the oral semaglutide achieved its own cardiovascular-risk-reduction indication via the SOUL trial, alleviate long-standing concerns and solidify its position as a transformative therapy. The news from today** emphasizes a dynamic and evolving field, promising continued progress in patient care.